Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Otol Neurotol. 2012 Feb;33(2):244–257. doi: 10.1097/MAO.0b013e31823e287f

Figure 6. Growth inhibition of primary VS and malignant schwannoma HMS-97 cells by Erlotinib and Lapatinib.

Figure 6

Figure 6

Figure 6

Figure 6

Three VS cultures (A) and HMS-97 cells (B) were treated various doses of Erlotinib and cell proliferation was determined using MTS assays. Similarly, cultured VS (C) and HMS-97 cells (D) were treated with the indicated doses of Lapatinib and assayed for cell proliferation.